Back

Low-dose rivaroxaban plus aspirin for elderly patients with symptomatic peripheral artery disease: is it worth the bleeding risk?

European Heart Journal

3 September 2021
Organised by: Logo
Read full article
ESC Journals DISEASES OF THE AORTA, PERIPHERAL VASCULAR DISEASE, STROKE Peripheral Vascular and Cerebrovascular Disease

Contributors

Juqian Zhang
Juqian Zhang

Author

S R Vallabhaneni
S R Vallabhaneni

Author

Gregory Y H Lip
Gregory Y H Lip

Author

University of Liverpool Liverpool , United Kingdom of Great Britain & Northern Ireland

You may be interested in
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
19 July 2023
thumbnail
Congress Presentation
Direct oral anticoagulant rivaroxaban in very old and frail patients: A one-year prospective follow-up of a large-scale cohort (SAFIR-AC)
31 August 2019
thumbnail
Congress Presentation
The impact of statin treatment intensity after endovascular revascularization for lower extremity peripheral artery disease
27 August 2022
thumbnail
Congress Presentation
Low-dose anticoagulation for peripheral deep vein thrombosis of the lower extremities in cancer patients
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources